What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Fabio Turco; Andrew Armstrong; Gerhardt Attard; Tomasz M. Beer; Himisha Beltran; Anders Bjartell; Alberto Bossi; Alberto Briganti; Rob G. Bristow; Muhammad Bulbul; Orazio Caffo; Kim N. Chi; Caroline Clarke; Noel Clarke; Ian D. Davis; Johann de Bono; Ignacio Duran; Ros Eeles; Eleni Efstathiou; Jason Efstathiou; Christopher P. Evans; Stefano Fanti; Felix Y. Feng; Karim Fizazi; Mark Frydenberg; Dan George; Martin Gleave; Susan Halabi; Daniel Heinrich; Celestia Higano; Michael S. Hofman; Maha Hussain; Nicholas James; Rob Jones; Ravindran Kanesvaran; Raja B. Khauli; Laurence Klotz; Raya Leibowitz; Christopher Logothetis; Fernando Maluf; Robin Millman; Alicia K. Morgans; Michael J. Morris; Nicolas Mottet; Hind Mrabti; Declan G. Murphy; Vedang Murthy; William K. Oh; Ngozi Ekeke Onyeanunam; Piet Ost; Joe M. O'Sullivan; Anwar R. Padhani; Christopher Parker; Darren M.C. Poon; Colin C. Pritchard; Danny M. Rabah; Dana Rathkopf; Robert E. Reiter; Mark Rubin; Charles J. Ryan; Fred Saad; Juan Pablo Sade; Oliver Sartor; Howard I. Scher; Neal Shore; Iwona Skoneczna; Eric Small; Matthew Smith; Howard Soule; Daniel Spratt; Cora N. Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew Sydes; Mary Ellen Taplin; Derya Tilki; Bertrand Tombal; Levent Türkeri; Hiroji Uemura; Hirotsugu Uemura; Inge van Oort; Kosj Yamoah; Dingwei Ye; Almudena Zapatero; Silke Gillessen; Aurelius Omlin

doi:10.1016/j.eururo.2022.02.010

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Fabio Turco^*, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline Clarke, Noel Clarke, Ian D. Davis, Johann de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason EfstathiouChristopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celestia Higano, Michael S. Hofman, Maha Hussain, Nicholas James, Rob Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Christopher Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Ngozi Ekeke Onyeanunam, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Christopher Parker, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew Sydes, Mary Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Türkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Silke Gillessen, Aurelius Omlin

^*Corresponding author for this work

Oncology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

Original language	English
Pages (from-to)	6-11
Number of pages	6
Journal	European Urology
Volume	82
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2022.02.010
State	Published - Jul 2022

Funding

Funders	Funder number
UK Research and Innovation	103491

Keywords

COVID-19 boost injection
COVID-19 pandemic
COVID-19 vaccine
Prostate cancer
Prostate cancer management
Telemedicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2022.02.010

Cite this

Turco, F., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., Caffo, O., Chi, K. N., Clarke, C., Clarke, N., Davis, I. D., de Bono, J., Duran, I., Eeles, R., Efstathiou, E., ... Omlin, A. (2022). What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 82(1), 6-11. https://doi.org/10.1016/j.eururo.2022.02.010

@article{991328d91b8f4932ba789b2ab6c0ceff,

title = "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021",

abstract = "Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.",

keywords = "COVID-19 boost injection, COVID-19 pandemic, COVID-19 vaccine, Prostate cancer, Prostate cancer management, Telemedicine",

author = "Fabio Turco and Andrew Armstrong and Gerhardt Attard and Beer, {Tomasz M.} and Himisha Beltran and Anders Bjartell and Alberto Bossi and Alberto Briganti and Bristow, {Rob G.} and Muhammad Bulbul and Orazio Caffo and Chi, {Kim N.} and Caroline Clarke and Noel Clarke and Davis, {Ian D.} and {de Bono}, Johann and Ignacio Duran and Ros Eeles and Eleni Efstathiou and Jason Efstathiou and Evans, {Christopher P.} and Stefano Fanti and Feng, {Felix Y.} and Karim Fizazi and Mark Frydenberg and Dan George and Martin Gleave and Susan Halabi and Daniel Heinrich and Celestia Higano and Hofman, {Michael S.} and Maha Hussain and Nicholas James and Rob Jones and Ravindran Kanesvaran and Khauli, {Raja B.} and Laurence Klotz and Raya Leibowitz and Christopher Logothetis and Fernando Maluf and Robin Millman and Morgans, {Alicia K.} and Morris, {Michael J.} and Nicolas Mottet and Hind Mrabti and Murphy, {Declan G.} and Vedang Murthy and Oh, {William K.} and {Ekeke Onyeanunam}, Ngozi and Piet Ost and O'Sullivan, {Joe M.} and Padhani, {Anwar R.} and Christopher Parker and Poon, {Darren M.C.} and Pritchard, {Colin C.} and Rabah, {Danny M.} and Dana Rathkopf and Reiter, {Robert E.} and Mark Rubin and Ryan, {Charles J.} and Fred Saad and {Pablo Sade}, Juan and Oliver Sartor and Scher, {Howard I.} and Neal Shore and Iwona Skoneczna and Eric Small and Matthew Smith and Howard Soule and Daniel Spratt and Sternberg, {Cora N.} and Hiroyoshi Suzuki and Christopher Sweeney and Matthew Sydes and Taplin, {Mary Ellen} and Derya Tilki and Bertrand Tombal and Levent T{\"u}rkeri and Hiroji Uemura and Hirotsugu Uemura and {van Oort}, Inge and Kosj Yamoah and Dingwei Ye and Almudena Zapatero and Silke Gillessen and Aurelius Omlin",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = jul,

doi = "10.1016/j.eururo.2022.02.010",

language = "אנגלית",

volume = "82",

pages = "6--11",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "1",

}

Turco, F, Armstrong, A, Attard, G, Beer, TM, Beltran, H, Bjartell, A, Bossi, A, Briganti, A, Bristow, RG, Bulbul, M, Caffo, O, Chi, KN, Clarke, C, Clarke, N, Davis, ID, de Bono, J, Duran, I, Eeles, R, Efstathiou, E, Efstathiou, J, Evans, CP, Fanti, S, Feng, FY, Fizazi, K, Frydenberg, M, George, D, Gleave, M, Halabi, S, Heinrich, D, Higano, C, Hofman, MS, Hussain, M, James, N, Jones, R, Kanesvaran, R, Khauli, RB, Klotz, L, Leibowitz, R, Logothetis, C, Maluf, F, Millman, R, Morgans, AK, Morris, MJ, Mottet, N, Mrabti, H, Murphy, DG, Murthy, V, Oh, WK, Ekeke Onyeanunam, N, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Rubin, M, Ryan, CJ, Saad, F, Pablo Sade, J, Sartor, O, Scher, HI, Shore, N, Skoneczna, I, Small, E, Smith, M, Soule, H, Spratt, D, Sternberg, CN, Suzuki, H, Sweeney, C, Sydes, M, Taplin, ME, Tilki, D, Tombal, B, Türkeri, L, Uemura, H, Uemura, H, van Oort, I, Yamoah, K, Ye, D, Zapatero, A, Gillessen, S & Omlin, A 2022, 'What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021', European Urology, vol. 82, no. 1, pp. 6-11. https://doi.org/10.1016/j.eururo.2022.02.010

TY - JOUR

T1 - What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic

T2 - Report from the Advanced Prostate Cancer Consensus Conference 2021

AU - Turco, Fabio

AU - Armstrong, Andrew

AU - Attard, Gerhardt

AU - Beer, Tomasz M.

AU - Beltran, Himisha

AU - Bjartell, Anders

AU - Bossi, Alberto

AU - Briganti, Alberto

AU - Bristow, Rob G.

AU - Bulbul, Muhammad

AU - Caffo, Orazio

AU - Chi, Kim N.

AU - Clarke, Caroline

AU - Clarke, Noel

AU - Davis, Ian D.

AU - de Bono, Johann

AU - Duran, Ignacio

AU - Eeles, Ros

AU - Efstathiou, Eleni

AU - Efstathiou, Jason

AU - Evans, Christopher P.

AU - Fanti, Stefano

AU - Feng, Felix Y.

AU - Fizazi, Karim

AU - Frydenberg, Mark

AU - George, Dan

AU - Gleave, Martin

AU - Halabi, Susan

AU - Heinrich, Daniel

AU - Higano, Celestia

AU - Hofman, Michael S.

AU - Hussain, Maha

AU - James, Nicholas

AU - Jones, Rob

AU - Kanesvaran, Ravindran

AU - Khauli, Raja B.

AU - Klotz, Laurence

AU - Leibowitz, Raya

AU - Logothetis, Christopher

AU - Maluf, Fernando

AU - Millman, Robin

AU - Morgans, Alicia K.

AU - Morris, Michael J.

AU - Mottet, Nicolas

AU - Mrabti, Hind

AU - Murphy, Declan G.

AU - Murthy, Vedang

AU - Oh, William K.

AU - Ekeke Onyeanunam, Ngozi

AU - Ost, Piet

AU - O'Sullivan, Joe M.

AU - Padhani, Anwar R.

AU - Parker, Christopher

AU - Poon, Darren M.C.

AU - Pritchard, Colin C.

AU - Rabah, Danny M.

AU - Rathkopf, Dana

AU - Reiter, Robert E.

AU - Rubin, Mark

AU - Ryan, Charles J.

AU - Saad, Fred

AU - Pablo Sade, Juan

AU - Sartor, Oliver

AU - Scher, Howard I.

AU - Shore, Neal

AU - Skoneczna, Iwona

AU - Small, Eric

AU - Smith, Matthew

AU - Soule, Howard

AU - Spratt, Daniel

AU - Sternberg, Cora N.

AU - Suzuki, Hiroyoshi

AU - Sweeney, Christopher

AU - Sydes, Matthew

AU - Taplin, Mary Ellen

AU - Tilki, Derya

AU - Tombal, Bertrand

AU - Türkeri, Levent

AU - Uemura, Hiroji

AU - Uemura, Hirotsugu

AU - van Oort, Inge

AU - Yamoah, Kosj

AU - Ye, Dingwei

AU - Zapatero, Almudena

AU - Gillessen, Silke

AU - Omlin, Aurelius

PY - 2022/7

Y1 - 2022/7

N2 - Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

AB - Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

KW - COVID-19 boost injection

KW - COVID-19 pandemic

KW - COVID-19 vaccine

KW - Prostate cancer

KW - Prostate cancer management

KW - Telemedicine

UR - http://www.scopus.com/inward/record.url?scp=85127502676&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2022.02.010

DO - 10.1016/j.eururo.2022.02.010

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 35393158

AN - SCOPUS:85127502676

SN - 0302-2838

VL - 82

SP - 6

EP - 11

JO - European Urology

JF - European Urology

IS - 1

ER -

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this